A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Inclusion Criteria: * Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least 1 prior systemic therapy (Part A) * Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1 * Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A * Adequate baseline hematologic, renal, and hepatic function * Patients for whom there is no further standard therapy available at the time of enrollment (Part A) * Patients with a histologically-confirmed, advanced solid malignancy meeting one of the following criteria: (1) indication for which pembrolizumab is approved or (2) relapsed, refractory, or progressive disease following at least 1 prior therapy and for which no further standard therapy is a available (Parts C and D) Exclusion Criteria: * Patients with carcinomatous meningitis or active central nervous system (CNS) metastases * Patients with recent (within 14 days) or serious ongoing infection * Patients requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalents) or immunosuppressive medications within 14 days of enrollment * Patients with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology therapy * Known active or latent tuberculosis * Uncontrolled diabetes mellitus * History of interstitial lung disease * Gastrointestinal abnormality that would affect absorption of SGN-2FF * Patients tested positive for hepatitis B or with a known, active hepatitis C infection * Women who are pregnant or breastfeeding * Patients with deep vein thrombosis (DVT) * Contraindication to prophylactic anticoagulation